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background:  Risk stratification for sudden death risk is now an essential component of disease management in hypertrophic 
cardiomyopathy (HCM), given the proven effectiveness of the implantable cardioverter-defibrillator (ICD) in terminating lethal ventricular 
tachyarrhythmias and preventing sudden death (SD). While highly useful in identifying high-risk patients, the stratification algorithm 
currently in use remains incomplete and novel strategies are encouraged.
Methods: . We evaluated the recently-promoted European Society of Cardiology (ESC) risk assessment strategy which employs 
sophisticated mathematical/statistical modeling using 7 disease variables to predict SD risk over 5 years. We calculated the ESC SD risk 
score and measured it against primary prevention ICD outcome in patients previously evaluated at 2 HCM referral centers.
results:  Of 372 study patients, 40 (10%) had appropriate ICD interventions at 43 ± 14 years of age, and 332 did not over a follow-
up period of 8.8 ± 6.0 years. The calculated ESC risk score and %/year risk for SD over 5 years did not differ between patients with 
or without device interventions (4.7 ± 2.5 vs. 4.1 ± 2.8 and 0.94%/year vs. 0.82%/year; P = 0.18). Most patients who experienced 
appropriate ICD interventions for VT/VF (n = 22; 55%) paradoxically had low SD risk scores of <4% /year over 5 years, judged to not 
justify ICD recommendations by the ESC model. Just 11 or 27% of those patients with appropriate ICD interventions had a high-risk 
ESC score (>6% risk/year over 5 years), considered a direct ICD indication, although 75% of those patients also met standard criteria 
for device implantation. Alternatively, most patients (205; 61%) without appropriate shocks had low risk scores (<4%/year), indicating a 
recommendation against ICD implant.
Conclusion:  In this large HCM cohort implanted with ICDs, ESC mathematical model and stratification strategy did not reliably predict 
SD risk, and the majority of patients who experienced appropriate ICD interventions would not have been considered candidates for 
prophylactic device therapy. Use of this scoring system as a primary risk stratifier would leave many high-risk HCM patients unprotected 
from arrhythmic SD.
